title: [Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism].
abstract: OBJECTIVE
  evaluate the efficacy of an estroprogestin EP containing 20 mcg ethinilestradiol (EE) and 3 mg drospirenone (DRSP) in the treatment of hyperandrogenism.
  
  
  METHODS
  In this study, twenty hyperandrogenic patients were treated with an EP containing EE 20 mcg and DRSP 3 mg in 24+4 regimen for three months. Skin evaluation was performed both quantitatively and qualitatively.
  
  
  CONCLUSIONS
  This EP combination showed, after a short-term treatment (three months) to decrease significantly seborrhea, acne, and circulating androgens (testosterone, deidroepiandrosterone sulphate, and androstenedione), while increased sex hormone binding globulin levels. Moreover, this EE 20 mcg/DRSP 3mg EP combination changed some parameters of skin quality, increasing corneometry (a parameter related to skin hydration), and reduced trans epidermal water loss (TEWL, a parameter related to skin evaporation), and erythema (a parameter related to skin inflammation). These results could be taken into account in individualizing the treatment of hyperandrogenic patients.
authors.affiliation: Servizio di Ginecologia Endocrinologica e Fisiopatologia della Menopausa, IRCCS-Istituto Dermopatico dell'Immacolata, Rome, Italia. lellostefano@libero.it
authors.forename: S
authors.initials: S
authors.lastname: Lello
authors.forename: V
authors.initials: V
authors.lastname: Pacifico
authors.forename: G
authors.initials: G
authors.lastname: Primavera
authors.forename: F
authors.initials: F
authors.lastname: Guardianelli
authors.forename: R
authors.initials: R
authors.lastname: Sorge
authors.forename: A M
authors.initials: AM
authors.lastname: Paoletti
authors.forename: G B
authors.initials: GB
authors.lastname: Melis
authors.forename: D
authors.initials: D
authors.lastname: Raskovic
authors.forename: L
authors.initials: L
authors.lastname: Colonna
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000008:administration & dosage*; D004338:Drug Combinations; D004967:Estrogens / Q000008:administration & dosage*; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000175:diagnosis / Q000188:drug therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage*; D009652:Norpregnenes; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D004338:Drug Combinations; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D009652:Norpregnenes; C494367:estroprogestin; D004997:Ethinyl Estradiol; C035144:drospirenone